Cardinal Health Recalls Butorphanol Tartrate Nasal Solution Due to Temperature Excursions
Cardinal Health Inc. is recalling 38 bottles of Butorphanol Tartrate Nasal Solution due to intermittent temperature excursions during storage.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, and the source text does not report any illnesses or injuries, fitting the criteria for a moderate severity score.
Plain-English summary
Cardinal Health Inc. is recalling 38 bottles of Butorphanol Tartrate Nasal Solution USP 10 mg/mL, 2.5 mL bottles. The product is identified by NDC 60505-0813-1 and lot code RT7113. It was manufactured by Apotex Inc. in Toronto, Ontario, Canada.
The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations, specifically intermittent exposure to temperature excursions during storage. The affected units were distributed to Florida, Georgia, and South Carolina.
Consumers and healthcare providers should discontinue use of the recalled product and contact their healthcare provider or pharmacist for further instructions.
The recalled product
- Product
- BUTORPHANOL TARTRATE (BUTORPHANOL TARTRATE)
- Brand
- BUTORPHANOL TARTRATE
- Manufacturer
- Cardinal Health Inc.
- Category
- Drug — Nasal Solution
- Hazard
- Affected units
- 38
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- RT7113
Distribution
Part of a larger recall action
This product is one of 198 recalled by Cardinal Health Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 198 products in this recall →Related recalls
Same manufacturer · Cardinal Health Inc.
See all →- HighEnoxaparin syringe bags recalled after being labeled with the wrong strength
FDA (Drugs) · 2025-09-03
- ModerateXolair auto-injectors exposed to temperatures outside labeled storage requirements
FDA (Drugs) · 2025-08-13
- ModerateRecombinate antihemophilic factor vials exposed to temperatures outside labeled storage
FDA (Drugs) · 2025-08-13
- ModerateXolair 75 mg syringes exposed to temperatures outside labeled storage requirements
FDA (Drugs) · 2025-08-13
- ModerateWegovy injection recalled due to temperature exposure during shipping
FDA (Drugs) · 2025-05-07
Same hazard · temperature excursion
See all →- ModerateCyclophosphamide injection vials recalled after a transportation temperature excursion
FDA (Drugs) · 2025-09-24
- ModerateProlia prefilled syringes recalled after potential temperature excursions during transit delays
FDA (Drugs) · 2025-07-30
- ModerateBenlysta vials recalled after potential temperature excursions during transit delays
FDA (Drugs) · 2025-07-30
- ModerateEvenity prefilled syringes recalled after potential temperature excursions during transit delays
FDA (Drugs) · 2025-07-30